Last edition
News about "Wockhardt"
Wockhardt's Zaynich Gets CDSCO SEC Nod for Gram-Negative Infections
CDSCO’s Subject Expert Committee (SEC) recommends Wockhardt’s Zaynich (Zidebactam/Cefepime) for Gram-negative infections, paving the way for DCGI approval of the novel antibiotic in India.
Wockhardt | 30/03/2026 | By News Bureau | 149
EMA Grants Accelerated Assessment to WCK 5222 by Wockhardt
The European Medicines Agency (EMA) has granted Accelerated Assessment status to Wockhardt’s WCK 5222, a fixed-dose combination of zidebactam and cefepime, following a pre-submission meeting—potentially enabling a faster regulatory review of the novel antibiotic therapy.
Wockhardt | 02/01/2026 | By News Bureau | 249
Senores Pharmaceuticals Inks SPA to Raise Stake in Havix
Senores Pharmaceuticals Ltd. (SPL) has entered into a Share Purchase Agreement (SPA) with a public shareholder of Havix Group Inc., doing business as Aavis Pharmaceuticals (Havix), to acquire 6,730 equity shares — representing 2.97 percent of Havix’s total paid-up share capital.
Wockhardt | 14/07/2025 | By Dineshwori | 360
Wockhardt Realigns US Operations to Focus on Innovative Portfolio, Exits Generic Pharma Segment
Wockhardt has announced a strategic realignment of its US operations, exiting the loss-making generics business to focus on its innovation-led priorities in novel antibiotics and biologics, marking a decisive shift toward building a differentiated, future-ready pharmaceutical enterprise.
Wockhardt | 11/07/2025 | By Mrinmoy Dey | 436
Wockhardt | 28/06/2022 | By Sudeep Soparkar | 726
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy